知镜 Cognispect · 医学文献与研究工作台

Clinical manifestations of primary aldosteronism and cardiometabolic risk.

Pascual-Corrales E, Ruiz-Cánovas JM, Peña MMP.
Vitamins and hormones · 2025-12-29 · PMID 41638805

文献摘要

Primary aldosteronism (PA) is the most common cause of secondary hypertension and is increasingly recognized as a spectrum disorder, ranging from subclinical to overt forms. Clinical manifestations include hypertension, often resistant, and may be accompanied by hypokalemia. Beyond BP elevation, PA is associated with a disproportionately high risk of cardiovascular and metabolic complications compared to essential hypertension, including coronary artery disease, arrhythmias, heart failure, left ventricular hypertrophy, stroke, metabolic syndrome and impaired glucose metabolism. The negative effects of aldosterone excess induce greater target organ damage than seen in primary hypertension, including arterial stiffness, cardiac remodeling, and renal dysfunction. Targeted treatments such as mineralocorticoid receptor (MR) antagonists and adrenalectomy have demonstrated efficacy in reducing these risks and improving patient outcomes. Therefore, early detection and management of PA are essential for preventing long-term cardiovascular and metabolic complications.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。